Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 22, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan"). As a result of a fund movement on September 21, 2006, the holdings increased from 17,356,021 to 17,371,143 shares. The transaction occurred at an average price of $55.40.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Plan is a discretionary fund for employees and former employees, and that two directors, Dr. J.P. Garnier and Dr. M.M. Slaoui, are potentially interested in the shares held in the fund in the same manner as other beneficiaries.
Key Facts for Investor Verification
- Transaction Date: September 21, 2006 (notified September 22, 2006).
- Entity Involved: GlaxoSmithKline US Retirement Savings Plan.
- Share Change: Increase of 15,122 ADRs (from 17,356,021 to 17,371,143).
- Average Price: $55.40 per ADR.
- Directors Affected: Dr. J.P. Garnier and Dr. M.M. Slaoui (as potential beneficiaries).